Listed

Twist Bioscience Corp: Form 10-Q/A for the period ended Dec 31, 2025

Filed with the SEC on Feb 26, 2026 and accepted by EDGAR at Feb 26, 2026, 16:19 ET.

Share

Management's discussion and analysis

As filed, 19,372 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

You should read the following discussion and analysis of our financial condition and results of operations together with the unaudited condensed consolidated financial statements and related notes that are included elsewhere in this Form 10-Q and our Annual Report on Form 10-K. This discussion contains forward-looking statements based upon current plans, expectations and beliefs that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, those discussed in the section entitled “Risk Factors” and elsewhere in this Form 10-Q. In preparing this MD&A, we presume that readers have access to and have read the MD&A in our Annual Report on Form 10-K, pursuant to Instruction 2 to paragraph (b) of Item 303 of Regulation S-K.

Overview

We offer customizable solutions across the biological continuum. We have developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of our platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. We have combined our silicon-based DNA writing technology with proprietary software, scalable commercial infrastructure and an e-commerce platform to create an integrated technology platform that enables us to achieve high levels of quality, precision, automation, and manufacturing throughput at a significantly lower cost than our competitors. We have applied our unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing, or NGS, sample preparation, and antibody libraries for drug discovery and development, all designed to enable our customers to conduct research more efficiently and effectively. Leveraging our same technology, we have expanded our footprint beyond DNA synthesis to manufacture synthetic RNA as well as express antibody proteins and conduct many diverse assays to characterize these proteins. We have further expanded our offering to deliver data from the characterization of antibody proteins to our customers and partners.

We believe our products enable a broad range of applications that may ultimately improve health and the sustainability of the planet across multiple industries including therapeutics, diagnostics, industry and applied, academic research and government, and global supply partners revenue. We sell our synthetic DNA and synthetic DNA-based products to a customer base of more than 3,800 customers annually across a broad range of industries. In order to address this diverse customer base, we employ a multi-channel strategy comprised of a direct sales force targeting synthetic DNA customers, a direct sales force focusing on the NGS market and an e-commerce platform that serves both commercial channels. We employ business development and sales representatives for our protein solutions and biologics discovery service offering. Our easy-to-use e-commerce platform allows customers to design, validate and place on-demand orders of customized DNA online, and enables them to receive real-time customized quotes for their products and track their order status through the manufacturing and delivery process. This is a critical part of our strategy to address our large markets and diverse customer base, as well as drive commercial productivity, enhance the customer experience, and promote loyalty.

We generate revenue through our DNA synthesis and protein solutions as well as our NGS applications. As we have moved further up the value chain from fragments to genes to preps to proteins and beyond, the strategic connection between what we previously described as our "synthetic biology" portfolio and "biopharma services" tightens. Beginning fiscal 2026, we combined revenue from synthetic biology tools and biopharma services into a new category called DNA synthesis and protein solutions. Additionally, we renamed NGS tools to NGS applications to better reflect their role in DNA sequencing workflows.

Since our inception, we have incurred net losses each year. Our net loss for the three months ended December 31, 2025 was $30.5 million compared to a net loss of $31.6 million for the three months ended December 31, 2024. As of December 31, 2025, we have accumulated net deficit of $1,350.1 million and cash, cash equivalents and short-term investments of $197.9 million. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the success of our existing products and the development and commercialization of additional products in the synthetic biology and biologic drug industries as well as leveraging our investment in our manufacturing facility in Wilsonville, Oregon.

Financial highlights from three months ended December 31, 2025, compared to the three months ended December 31, 2024, include the following:

  • Revenues growth of 16.9% to $103.7 million from $88.7 million, primarily due to growth in NGS Applications and DNA Synthesis and Protein Solutions revenues;
  • Gross margin increased to 52.0% from 48.3% primarily due to increases in revenues and driving additional cost savings through continuous process improvement initiatives;
  • Loss from operations decreased to $32.9 million from $34.6 million primarily due to an increase in both revenues and gross profit. Additionally, contributing factors were a decrease in research and development expenses, offset by an increase in selling, general and administrative expenses for the three months ended December 31, 2025;
  • Net cash used in operating activities increased to $24.8 million from $21.4 million.

Results of Operations

Comparison of the Three Months Ended December 31, 2025 and 2024

Revenues

(in thousands, except percentages)

Three months ended December 31, 2025 2024 Change%
Revenues $103,698 $88,713 $14,985 17%

Revenues by Geography

We have one reportable segment from the manufacturing of synthetic DNA products. The following table shows our revenues by geography, based on our customers’ shipping addresses. Americas consists of United States, Canada, Mexico and South America; EMEA consists of Europe, Middle East and Africa; and APAC primarily consists of Japan, China, South Korea, India, Singapore, Malaysia, Australia, New Zealand, Thailand and Taiwan.

Three months ended December 31,
(in thousands, except percentages) 2025% 2024%
Americas $58,381 56% $53,709 61%
EMEA 38,365 37% 28,304 30%
APAC 6,952 7% 6,700 9%
Total revenues $103,698 100% $88,713 100%

Revenues by Products

We historically reported our revenue by the following products: synthetic genes, oligo pools and DNA libraries (collectively, synthetic biology), antibody discovery, and NGS tools. Beginning fiscal 2026, we combined revenue from synthetic genes, oligo pools, DNA libraries, and biopharma services for antibody discovery into DNA synthesis and protein solutions. We also changed the name of NGS tools to NGS applications, as these products and services facilitate DNA reading and sequencing workflows. The table below summarizes revenues by the new products:

Three months ended December 31,
(in thousands, except percentages) 2025% 2024%
DNA synthesis and protein solutions 51,060 49% 40,071 45%
NGS applications 52,638 51% 48,642 55%
Total revenues $103,698 100% $88,713 100%

Revenues by Industry

We historically reported revenue by industrial chemicals/materials, academic research, healthcare, and food/agriculture. Beginning fiscal 2026, we will disclose revenue by therapeutics, diagnostics, industry and applied, academic research and government, and global supply partners revenue. These updated categories better align with our operations and increase clarity around our key customer groups. The table below summarizes revenues by industry:

Three months ended December 31,
(in thousands, except percentages) 2025% 2024%
Therapeutics $37,225 36% $26,772 30%
Diagnostics 35,315 34% 35,483 40%
Industry and applied 6,121 6% 5,528 6%
Academic research and government 12,217 12% 12,396 14%
Global supply partners 12,820 12% 8,534 10%
Total revenues $103,698 100% $88,713 100%

Product Shipments Including Synthetic Genes

The table below summarized product shipments including synthetic genes:

(in thousands)

Three months ended December 31, 2025 2024
Number of genes shipped 271 205

The number of customers who purchased products from us were approximately 2,538 and 2,376 customers for the three months ended December 31, 2025 and 2024, respectively.

Revenues increased 16.9% to $103.7 million for the three months ended December 31, 2025, as compared to $88.7 million for the three months ended December 31, 2024. The increase in revenues primarily reflects growth in NGS Applications revenue of 8.2% and growth in DNA Synthesis and Protein Solutions revenue of 27.4%, both of which are primarily attributable to increase in revenues from our customers in therapeutics, global supply partners, and industry and applied industries, primarily driven by an increase in number of customers. The number of genes shipped in the three months ended December 31, 2025, increased to approximately 271,000 genes, compared to approximately 205,000 genes in the three months ended December 31, 2024, an increase of 32.2%.

Cost of Revenues

(in thousands, except percentages)

Three months ended December 31, 2025 2024 Change%
Cost of revenues $49,726 $45,873 $3,853 8%
Gross profit $53,972 $42,840 $11,132 26%
Gross margin 52.0% 48.3% 3.7%

Cost of revenues increased 8% to $49.7 million for the three months ended December 31, 2025, as compared to $45.9 million for the three months ended December 31, 2024. The increase is primarily attributable to an increase in material costs of $2.7 million driven by increased sales and a $1.4 million increase in personnel costs. Gross margin increased 3.7% to 52.0% for the three months ended December 31, 2025, as compared to 48.3% in the same period of the prior year, mainly due to increase in revenues and driving additional cost savings through continuous process improvement initiatives.

Research and Development Expenses

(in thousands, except percentages)

Three months ended December 31, 2025 2024 Change%
Research and development $17,130 $21,307 $(4,177) (20)%

Research and development expenses decreased 20% to $17.1 million for the three months ended December 31, 2025, as compared to $21.3 million for the three months ended December 31, 2024. The decrease is primarily driven by a $2.6 million decrease in personnel costs, including a $1.1 million decrease in stock-based compensation expenses, a $0.9 million decrease in outside services costs, and a $0.6 million decrease in costs for facilities and depreciation and amortization. These decreases are largely attributable to the sale of our DNA digital data storage business in fiscal year 2025.

Selling, General and Administrative Expenses

(in thousands, except percentages)

Three months ended December 31, 2025 2024 Change%
Selling, general and administrative $69,742 $56,177 $13,565 24%

Selling, general and administrative expenses increased 24% to $69.7 million for the three months ended December 31, 2025, as compared to $56.2 million for the three months ended December 31, 2024. The increase is primarily attributable to a $7.7 million increase in personnel costs, including a $2.4 million increase in stock-based compensation expense, and a $5.4 million increase in outside services costs as we continue to scale our commercial organization and invest into our corporate infrastructure.

Interest and Other Income (Expense), net

(in thousands, except percentages)

Three months ended December 31, 2025 2024 Change%
Interest income $2,175 $3,240 $(1,065) (33)%
Other income (expense), net 471 (93) 564 (606)%
Total interest and other income (expense), net $2,646 $3,147 $(501) (16)%

Interest income decreased 33% to $2.2 million for the three months ended December 31, 2025, as compared to $3.2 million for the three months ended December 31, 2024, due to lower cash equivalents and short-term investments balances and lower interest rates.

Income Tax Expense

(in thousands, except percentages)

Three months ended December 31, 2025 2024 Change%
Income tax expense $(253) $(97) $(156) 161%

We recorded an income tax provision of $0.3 million and $0.1 million for the three months ended December 31, 2025 and December 31, 2024, respectively.

Liquidity and Capital Resources

Sources of Liquidity

To date, we have financed our operations principally through public equity raises, private placements of our convertible preferred stock, borrowings from credit facilities, proceeds from the royalty purchase agreement, sale of DNA digital data storage assets and revenue from our commercial operations. At December 31, 2025, we had a balance of $148.6 million of cash and cash equivalents and $49.4 million in short-term investments.

Operating Capital Requirements

Our primary uses of capital are, and we expect will continue to be for the near future, compensation and related expenses, manufacturing costs, laboratory and related supplies, legal and other regulatory expenses and general overhead costs, including facilities costs and capital expenditures. We had $12.9 million in commitments for capital expenditures as of December 31, 2025.

Cash Flows

The following table summarizes our sources and uses of cash and cash equivalents:

(in thousands)

Three months ended December 31, 2025 2024
Net cash used in operating activities $(24,814) $(21,428)
Net cash provided by (used in) investing activities (9,933) (1,536)
Net cash provided by financing activities 298 17,944

Operating Activities

Net cash used in operating activities was $24.8 million during the three months ended December 31, 2025, which was primarily due to a net loss of $30.5 million, adjusted for non-cash items, including depreciation and amortization of $6.2 million, stock-based compensation expense of $13.3 million, and a net cash outflow from operating assets and liabilities of $13.4 million. The net cash outflow from operating assets and liabilities was mainly due to increases in inventories of $4.6 million and prepaid and other current assets of $7.7 million, and a decrease in accrued compensation of $12.4 million, partially offset by increase in accounts receivable of $6.8 million, due to the increase in revenues and the timing of collections, and decreases in accounts payable of $1.5 million, other liabilities of $1.3 million and accrued expenses of $1.5 million. The changes in accrued compensation, accrued expenses, and accounts payable are due to timing of payments to vendors and employees.

Net cash used in operating activities was $21.4 million during the three months ended December 31, 2024, which was primarily due to a net loss of $31.6 million, adjusted for non-cash items, including depreciation and amortization of $6.4 million, stock-based compensation expense of $12.0 million, and a net cash outflow from operating assets and liabilities of $8.2 million. The net cash outflow from operating assets and liabilities was mainly due to an increase in accounts receivable of $4.5 million due to timing of collections, a decrease in accrued compensation of $11.9 million offset by increases in accrued expenses of $3.1 million and accounts payable of $5.7 million. The changes in accrued compensation, accrued expenses, and accounts payable are due to timing of payments to vendors and employees.

Investing Activities

Net cash used in investing activities was $9.9 million during the three months ended December 31, 2025, which consisted of the purchases of property and equipment of $10.0 million.

Net cash used in investing activities was $1.5 million during the three months ended December 31, 2024, which consisted of the purchases of laboratory property, equipment and computers of $2.3 million offset by the proceeds from the net impact of purchases and maturity of investments of $0.7 million.

Financing Activities

Net cash provided by financing activities was $0.3 million in the three months ended December 31, 2025, which consisted of $0.3 million from the exercise of stock options.

Net cash provided by financing activities was $17.9 million in the three months ended December 31, 2024, which consisted of $15.0 million from sale of future revenue and $3.0 million from the exercise of stock options.

Off-balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Contractual Obligations and Other Commitments

Our contractual obligations have not materially changed from those reported in our Annual Report on Form 10-K except for lease commitments. As of December 31, 2025, our operating lease liability was $98.1 million. See note 9, Leases of the notes to our condensed consolidated financial statements included elsewhere in this Form 10-Q for information on our operating lease commitments.

Critical Accounting Policies and Significant Management Estimates

The preparation of our Condensed Consolidated Financial Statements in accordance with generally accepted accounting principles in the United States of America requires management to make estimates and judgments that affect the reported amounts in the financial statements and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Actual results may differ significantly from these estimates. A summary of our critical accounting policies and estimates is presented in Part II, Item 7 of our Annual Report on Form 10-K. There were no changes to our critical accounting policies and estimates during the three months ended December 31, 2025.

Recent Issued Accounting Pronouncements

For a description of accounting changes and recent accounting pronouncements, including the expected dates of adoption and estimated effects, if any, on our condensed consolidated financial statements, see Note 2, “Summary of Significant Accounting Policies” in Item 1 of Part I of this Form 10-Q.

Market risk

As filed, 243 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Information about our market risk is presented in Part II, Item 7A “Quantitative and Qualitative Disclosures about Market Risk” of our Annual Report on Form 10-K. Our exposure to market risk has not changed materially since September 30, 2025.

Controls and procedures

As filed, 1,911 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2025, which is the end of the period covered by this Form 10-Q. Based on this evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures to ensure that information required to be disclosed by the Company in reports we file or submit under the Exchange Act is (i) recorded, processed, summarized, evaluated and reported, as applicable, within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures were effective as of December 31, 2025.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended December 31, 2025, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives, as specified above. Our management recognizes that any control system, no matter how well designed and operated, is based upon certain judgments and assumptions and cannot provide absolute assurance that its objectives will be met.

Risk factors

As filed, 814 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors and other cautionary statements described under the heading “Item 1A. Risk Factors” included in our Annual Report on Form 10-K filed with the SEC on November 17, 2025, which could materially affect our business, financial condition or future results. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition or future results. There have been no material changes in our risk factors from those described in our Annual Report on Form 10-K. We may disclose changes to risk factors or additional risk factors from time to time in our future filings with the SEC.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2025-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2025-10-01 to 2025-12-31$103.7mus-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
Cost of revenue3 months2025-10-01 to 2025-12-31$49.7mus-gaap:CostOfRevenue
Research and development3 months2025-10-01 to 2025-12-31$17.1mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2025-10-01 to 2025-12-31$69.7mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2025-10-01 to 2025-12-31−$32.9mus-gaap:OperatingIncomeLoss
Income tax3 months2025-10-01 to 2025-12-31$253.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2025-10-01 to 2025-12-31−$30.5mus-gaap:NetIncomeLoss
Diluted EPS3 months2025-10-01 to 2025-12-31−$0.50us-gaap:EarningsPerShareDiluted
Basic EPS3 months2025-10-01 to 2025-12-31−$0.50us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2025-10-01 to 2025-12-3161,080,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2025-10-01 to 2025-12-31−$24.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2025-10-01 to 2025-12-31$10.0mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2025-12-31$148.6mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2025-12-31$303.9mus-gaap:AssetsCurrent
Total assetsAt period end2025-12-31$638.1mus-gaap:Assets
Current liabilitiesAt period end2025-12-31$80.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2025-12-31$182.0mus-gaap:Liabilities
Shareholders' equityAt period end2025-12-31$456.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001581280-26-000029. Last ingested by Listed: Nov 12, 2026, 17:51 ET. Listed shows no prices and gives no investment advice.